Wayrilz (Rezabrutinib) is a novel Bruton's Tyrosine Kinase (BTK) inhibitor. Approved in the United States in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have had an inadequate response to previous therapies.

How to Purchase Wayrilz (Rezabrutinib)

Overseas Purchase

Patients may choose to consult and purchase Wayrilz at hospital pharmacies or licensed drugstores in countries/regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchase and Use of Wayrilz (Rezabrutinib)

Contraindications and Risk Warnings for Special Populations

Pregnant women: Based on animal data, rezabrutinib may cause fetal harm. Before initiating medication, verify the pregnancy status of women of reproductive age and instruct them to use effective contraceptive measures.

Lactating women: It is recommended to discontinue breastfeeding during treatment and for at least 1 week after the last dose.

Infection risk: BTK inhibitors may increase the risk of serious infections (including bacterial, viral, and fungal infections). Closely monitor for signs of infection during medication use.

Avoidance of Drug Interactions

CYP3A inhibitors/inducers: Avoid concurrent use with strong or moderate CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin).

Gastric acid regulators: Take rezabrutinib at least 2 hours before using antacids or H2 receptor antagonists, and avoid concurrent use with proton pump inhibitors (PPIs).

Active Monitoring of Adverse Reactions

Clinical studies show that the most common adverse reactions of rezabrutinib (incidence ≥ 10%) include diarrhea, nausea, headache, abdominal pain, and COVID-19 infection.

If persistent gastrointestinal symptoms or abnormal liver function (e.g., jaundice, dark urine) occur, seek medical attention immediately.

How to Identify Authenticity of Wayrilz (Rezabrutinib)

Verification of Packaging and Appearance

Authentic rezabrutinib is a 400 mg film-coated tablet, orange and capsule-shaped, with the letter "P" engraved on one side and "400" on the other side.

The drug packaging box must be clearly printed with the batch number, expiration date, and U.S. National Drug Code (NDC).

Verification of Official Information

Verify product information through the U.S. FDA official website or the anti-counterfeiting inquiry system of the manufacturer (Sanofi Group).

Confirmation of Storage Conditions

Authentic products should be stored in their original packaging, protected from light and hermetically sealed, within a temperature range of 20°C–25°C.

If packaging damage or abnormal storage conditions are found, the authenticity of the product should be questioned.